Biosimilars

Biosimilars are a rapidly growing treatment option for physicians treating advanced diseases, with more than 20 unique biosimilars expected to enter the U.S. healthcare market over the next decade. Learn more about these safe and effective treatment options.

RESOURCE
A Perfect Storm Brews for Biosimilar Marketing
Dr. Robert Rifkin, Oncologist and McKesson’s Biosimilar Medical Director, shares his thoughts on why we are entering the perfect storm for biosimilar marketing due to the growing clinical acceptance and continued cost containment pressures.
Read More

Read below for biosimilar resources at every stage: biosimilar beginners, considerations when using biosimilars, and best practices post-adoption.

New to biosimilars?

Biosimilars are biological products that are highly similar to and have no clinically meaningful differences from existing, FDA-approved reference biologics.
While biosimilars are similar to their reference biological product, they are not generic equivalents.
Biosimilars go through a rigorous FDA review process including analytical, animal and clinical studies.

Biosimilars go through an extensive FDA approval process and offer safe, effective therapeutic options for serious diseases

As more biosimilars become available in the U.S., providers, payers and patients all stand to benefit from further incorporating these safe and effective therapies throughout our healthcare ecosystem.

Rising healthcare costs, increasing drug production demands and reimbursement pressures are all putting a serious strain on our nation’s healthcare delivery system. By adopting biosimilars routinely into patient treatment decisions, we can improve overall access to critical, life-saving drugs all while reducing the costs of these expensive therapies through increased competition.

Learn more about the McKesson services available to support biosimilar and other practice needs by visiting our Solutions for Specialty Practices page.

Considering adopting biosimilars in your treatment regimens?

Biosimilars Currently Available through McKesson Include:
Biosimilar Drug	Biologic Reference Drug	HCPCS Code?	Patient Support Services	Full Prescribing Information
Mvasi (bevacizumab-awwb)	Avastin	Q5107	Amgen Assist 360	FDA Drug Info (PDF, 627 KB)
Zirabev (bevacizumab-bvzr)	Avastin	Q5118	Pfizer Oncology Together	FDA Drug Info (PDF, 1 MB)
Retacrit (epoetin alfa-epbx)	Epogen/Procrit	Q5105 (ESRD use) Q5106 (non-ESRD use)	Pfizer enCompassProgram	FDA Drug Info (PDF, 614 KB)
Herzuma (trastuzumab-pkrb)	Herceptin	Q5113	Teva Core Program	FDA Drug Info (PDF, 551 KB)
Kanjinti (trastuzumab-anns)	Herceptin	Q5117	Amgen Assist 360	FDA Drug Info (PDF, 834 KB)
Ogiviri (trastuzumab-dkst)	Herceptin	Q5114	Mylan Advocate Portal	FDA Drug Info
Ontruzant (trastuzumab-dttb)	Herceptin	Q5112	Merck Access Program	FDA Drug Info
Trazimera (trastuzumab-qyyp)	Herceptin	Q5116	Pfizer Oncology Together	FDA Drug Info (PDF, 706 KB)
Fulphila (pegfilgrastim-jmdb)	Neulasta	Q5108	Mylan Advocate Portal	FDA Drug Info (PDF, 921 KB)
Udenyca (pegfilgrastim-cbqv)	Neulasta	Q5111	Coherus COMPLETE \| Support	FDA Drug Info (PDF, 1 MB)
Ziextenzo (pegfilgrastim-bmez)	Neulasta	Q5120	Sandoz One Source	FDA Drug Info
Nivestym (filgrastim-aafi)	Neupogen	Q5110	Pfizer enCompass	FDA Drug Info (PDF, 921 KB)
Zarxio (filgrastim-sndz)	Neupogen	Q5101	Sandoz OneSource	FDA Drug Info (PDF, 3 MB)
Avsola (infliximab-axxq)	Remicade	Q5121	Amgen Assist	FDA Drug Info ?
Inflectra (infliximab-dyyb)	Remicade	Q5103	Pfizer enCompass	FDA Drug Info (PDF, 1 MB)
Renflexis (infliximab-abda)	Remicade	Q5104	Merck Access Program	FDA Drug Info (PDF, 537 KB)
Ruxience (rituximab-pvvr)	Rituxan	Q5119	Pfizer Oncology Together	FDA Drug Info (PDF, 811 KB)
Truxima (rituximab-abbs)	Rituxan	Q5115	Teva Core Program	FDA Drug Info (PDF, 402 KB)

********* Embedded Contact Object*******

Four Reasons to Consider Adopting Biosimilars for Your Treatment Regimens
Expand Treatment Options for Complex Diseases
Substantial Cost Savings on Expensive Therapies
FDA-Approved, Safe and Effective Treatments
Support from FDA and Other Leading Medical Advisory Organizations
BIOSIMILAR 101 RESOURCES
FDA Biosimilar Resources for Your Practice
Visit the FDA biosimilar website for provider and patient-facing biosimilar resources. Topics include the latest FDA approvals, biosimilar 101 education, regulatory review and approval, interchangeability guidance and more.
Learn More
ADDITIONAL READING
Biosimilar Perspectives from McKesson Experts
Three Biosimilar Barriers in Community Clinic
McKesson's Omar Hafez and Pete Perron discuss some of their takeaways working with biosimilars in the community clinic space.
From Clinical Use to Reimbursement
Dr. Robert Rifkin, medical director of biosimilars for McKesson, gives an update on biosimilar education and reimbursement.
Perfect Storm for Biosimilar Marketing
Dr. Robert Rifkin discusses the "perfect storm" for biosimilar marketing in a recent OncLive article.
Biosimilars: A Recent Review of Clinical Outcomes
A review of 14,000 individuals transitioned from a reference biologic medication to a biosimilar examines patient safety and treatment efficacy.
Overcoming Physician Barriers to Biosimilar Adoption in Clinics (PDF, 228 KB)
Omar Hafez shares how biopharmaceutical companies can learn how to overcome the clinical, operational, and economic barriers to biosimilar adoption.
VIEWPOINT
Biosimilar Endorsements From Major Medical Advisory Organizations
Read about the benefits of biosimilar growth from major Oncology and Rheumatology advisory bodies.
Rheumatology | Oncology?(PDF, 648 KB)
EDUCATION
CMS Medicare Guidance on Biosimilar Reimbursement
Stay up to date on new Medicare HCPCS codes and reimbursement guidance on biosimilars.
Learn More
Related McKesson Products and Services

Value-Based Care and Quality Payment Programs for Specialty Practices Meet the challenges of value-based care, from reducing costs to improving quality and reporting on performance metrics.
Visit Page

Oncology Practice Solutions From helping you control your drug spend to full-service practice management and everything in between, working with you to run your oncology practice efficiently and profitably is our specialty.
Visit Page